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We assessed the value of 18F-FDG uptake in the gallbladder
polyp (GP) in risk stratification for surgical intervention and the
optimal cutoff level of the parameters derived from GP 18F-FDG
uptake for differentiating malignant from benign etiologies in
a select, homogeneous group of patients with 1- to 2-cm
GPs. Methods: Fifty patients with 1- to 2-cm GPs incidentally
found on the CT portion of PET/CT were retrospectively analyzed.
All patients had histologic diagnoses. GP 18F-FDG activity was
visually scored positive ($liver) or negative (,liver). Maximal stan-
dardized uptake value of the GP (SUVgp) and ratio of SUVgp to
mean SUV of the liver (GP/L ratio) were also measured. Univariate
and multivariate logistic regression analyses were performed to
determine the utility of patient and clinical variables—that is, sex,
age, gallstone, polyp size, and three 18F-FDG–related parameters
in risk stratification. Results: Twenty GPs were classified as ma-
lignant and 30 as benign. Multivariate analyses showed that the
age and all parameters (visual criteria, SUVgp, and GP/L) related
to 18F-FDG uptake were significant risk factors, with the GP/L
being the most significant. The sex, size of GPs, and presence
of concurrent gallstones were found to be insignificant. Conclu-
sion: 18F-FDG uptake in a GP is a strong risk factor that can be
used to determine the necessity of surgical intervention more
effectively than other known risk factors. However, all criteria de-
rived from 18F-FDG uptake presented in this series may be
applicable to the assessment of 1- to 2-cm GPs.
Key Words: gallbladder polyp; gallbladder cancer; polypoid
lesion of gallbladder; PET; fluorodeoxyglucose
J Nucl Med 2012; 53:353–358
DOI: 10.2967/jnumed.111.093948
Increased use and improved quality of ultrasonography
has resulted in a significant increase in the prevalence of
gallbladder polyps (GPs). The prevalence of GP was re-
ported to be 5.6% in a large series with a sample size of
194,767 asymptomatic adults (1). Because the prognosis of
gallbladder cancer is extremely poor (2), accurate differen-
tiation between the malignant and benign GPs is essential.
A GP size of 1 cm or greater is considered an important risk
factor for malignancy requiring surgical intervention (3–5).
Other factors used for risk stratification, either for differen-
tiating malignant from benign lesions or for differentiating
neoplastic from nonneoplastic lesions, include age, the
number and shape of the GP, and the presence or absence
of concurrent gallstone (1,5–9). Some features on high-res-
olution ultrasonography, endoscopic ultrasonography, and
CT have been used to differentiate malignant from benign
gallbladder lesions (10) or to differentiate neoplastic from
nonneoplastic polyps (11–13). Although some investigators
reported excellent results (10), significant uncertainty re-
mains in the ability to differentiate benign from malignant
GPs (14) or even in the ability to differentiate neoplastic
from nonneoplastic polyps (15).
The utility of PET using 18F-FDG for differentiating ma-
lignant from benign gallbladder diseases has been reported
(16–18). However, these investigations were limited be-
cause of the relatively small sample size and heterogeneous
populations. For example, some patients had GPs whereas
others had gallbladder wall thickening without GP. In ad-
dition, these investigations were performed using single-
modality PET systems rather than PET/CT. Identification
of relatively hypometabolic GP may be difficult on PET
alone, potentially leading to errors in measurement of true
18F-FDG uptake value.
The purpose of this study was to assess the value of
increased 18F-FDG uptake in the GP in risk stratification for
surgical intervention and the optimal cutoff level of the
parameters derived from the 18F-FDG uptake in a select,
homogeneous group of patients with GPs. Specifically,
patients with diffuse gallbladder disease or gallbladder wall
thickening without GPs and those with either high or low
pretest probability of malignancy, for example, GPs of 2 cm
or greater or less than 1 cm, respectively, were excluded.
MATERIALS AND METHODS
Patients
After obtaining approval from the institutional review board,
we retrospectively reviewed the medical records of patients who
were incidentally found to have GPs on the diagnostic CT portion
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of 18F-FDG PET/CT studies and subsequently underwent chole-
cystectomy in our institution over a 4-y period. All 18F-FDG
studies were performed for indications unrelated to gallbladder
disease. Patients with diffuse gallbladder disease or wall thicken-
ing without GPs were not included. Among patients with GPs, the
following 3 groups of patients in whom the pretest probability of
malignancy is considered either very high or very low were addi-
tionally excluded: patients with radiologic findings already highly
suggestive of malignancy, for example, local invasion or metasta-
sis in the adjacent organs or pathologic lymphadenopathy; patients
with polyps larger than 2 cm in the greatest diameter; and patients
with polyps smaller than 1 cm in the greatest diameter. After
exclusion, there were 55 patients with 1- to 2-cm polyps. Of these,
5 patients elected to have clinical follow-up and 50 patients had
surgery. These 50 polyps in 50 patients were available for evalua-
tion. There were 26 women and 24 men, with a mean age of 59.5 y
(age range, 34–79 y). The indication for PET/CT included staging or
restaging lung cancer in 5 patients, colorectal cancer in 4 patients,
breast cancers in 3 patients, lymphoma in 2 patients, other known or
suspected malignancies in 8 patients, and cancer screening in 28
patients.
Final diagnosis was made by histology in all patients and
classified into 2 categories—malignant or benign. Adenomas con-
taining high-grade dysplasia or focal malignant transformation
were categorized as malignant for the purpose of this investigation
because surgery is indicated for such adenomas.
Imaging Procedures
All patients fasted for at least 6 h before the study and rested for
at least 1 h before the PET/CT scan. Blood glucose concentration
was measured and confirmed to be less than 140 mg/dL before
scanning. Approximately 5.5 MBq of 18F-FDG per kilogram of
body weight was administered intravenously, and the duration of
the uptake phase was 60 min. Examinations were performed using
a Biograph TruePoint 40 PET/CT scanner (Siemens Medical Sys-
tems, CTI), with an axial field of view of 21.6 cm and a spatial
resolution of 4.2 mm in full width at half maximum at 1 cm from
the center. A low-dose CT scan for attenuation correction was first
obtained, immediately followed by emission imaging from the
neck to mid thigh in 3-dimensional mode at 3 min per bed posi-
tion. The patient then underwent a diagnostic CT scan with in-
travenous contrast. PET data were reconstructed iteratively using
an ordered-subset expectation maximization algorithm, with the
low-dose CT datasets used for attenuation correction.
Image Interpretation and Analysis
Visual grading of 18F-FDG activity in GPs was performed with-
out knowledge of histology; 18F-FDG activity was scored positive
if similar to or greater than liver parenchymal activity or visually
clearly discernible and negative if lower or visually indiscernible
(Fig. 1). For semiquantitative analysis, a region of interest (ROI)
was placed over the identified GP. For GPs visualized on PET, the
ROI was placed over the entire 18F-FDG–avid lesion on the axial
PET images. However, if an accurate placement of the ROI on
PET was deemed difficult because of little activity or no clearly
discernible activity in the GP, the CT portion of the PET/CT study
was used to place the ROI. The maximal standardized uptake
value (SUV) in the GP (SUVgp) was recorded for each ROI. Mean
SUV of the liver was obtained from an ROI placed over an area
of homogeneous activity in the right lobe. Care was taken to
avoid the central area of large vascular structures and any areas
of increased 18F-FDG uptake that might represent tumor. The
ratio of SUVgp to mean SUV of the liver (GP/L ratio) was also
calculated.
Statistical Analysis
Statistical analyses were performed using MedCalc statistical
software (version 9.6.4.0; MedCalc Software). An independent
Student t test or Mann–Whitney test was used to compare the 4
continuous independent variables—that is, the age of patients, GP
size, SUVgp, and GP/L ratio—between the malignant and benign
groups. Then the cutoff values of these variables providing the
best separation between malignant and benign GPs were obtained
using the receiver-operating-characteristic analyses and used to
dichotomize the data. The diagnostic performance of these 4 cut-
off values and of 3 additional categoric variables (sex, gallstone,
and visual grading of 18F-FDG uptake in GPs) in differentiating
malignant from benign GPs was assessed by univariate logistic
regression analysis.
Independent variables with a P value of less than 0.25 identified
from the univariate analysis were included in the multivariate
logistic regression analysis. Of the 3 variables derived from the
18F-FDG uptake in the GPs (visual grading, SUVgp, and GP/L
ratio), only 1 variable that was associated with the lowest P value
and highest odds ratio was chosen to be included in the multivar-
iate analysis. In addition, McNemar tests were performed to com-
pare the performances of dichotomized visual, SUVgp, and GP/L
ratio criteria. The results were considered statistically significant if
the P value from the multivariate analysis was less than 0.05 and
the 95% confidence interval of the odds ratio did not include 1.
RESULTS
Twenty neoplastic polyps were categorized as malignant
(16 adenocarcinomas, 2 adenomas with focal malignant
transformation, and 2 adenomas with high-grade dyspla-
sia). There were 30 benign polyps, including 26 nonneo-
plastic (12 inflammatory polyps, 9 cholesterol polyps, 3
FIGURE 1. (Left) A 56-y-old woman with 1.6-cm GP demonstrating
increased 18F-FDG uptake (maximum SUV, 4.2; arrows) on PET/CT
(top) and PET (bottom). Final diagnosis was papillary adenocarci-
noma. (Right) A 73-y-old man with 1.3-cm GP that could not be
identified on PET alone (bottom) but was identified on PET/CT (top;
arrow). Polyp was eventually confirmed to be cholesterol polyp.
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adenomyomatosis, and 2 papillary epithelial hyperplasia)
and 4 neoplastic lesions (4 adenomas).
Table 1 shows the comparison of the mean or median
values of the continuous variables—that is, age, polyp size,
SUVgp, and GP/L ratio—between malignant and benign
lesions. There was no statistically significant difference in
size between malignant and benign polyps, most likely be-
cause of the narrow range (1–2 cm) selected for this in-
vestigation. However, despite the narrow size range, there
was a statistically significant difference in the age, SUVgp,
and GP/L ratio between malignant and benign polyps. The
GP/L ratio yielded the lowest P value, 0.0001.
The receiver-operating-characteristic analysis yielded an
age of 63 y, size of 1.2 cm, SUVgp of 2.1, and GP/L ratio of
1.14 to be the best cutoffs for each continuous variable,
with an area under the curve of 0.750, 0.642, 0.772, and
0.822, respectively. Table 2 summarizes the results of uni-
variate analyses of the 7 variables and those of multivariate
analyses of 3 selected variables. Of the 7 variables tested, the
sex and presence of concurrent gallstone did not show any
trend. The cutoff GP size of 1.2 cm yielded a marginal P
value of 0.052, which approached statistical significance; this
variable, therefore, was included in the multivariate logistic
regression analysis. The cutoff age of 63 y, visual 18F-FDG
uptake, SUVgp, and GP/L ratio were found to be significant
by univariate analyses. Of the 3 variables related to 18F-FDG
uptake, the GP/L ratio was associated with the lowest P
value, 0.00001, and the highest odds ratio, 36.8, and there-
fore chosen to be included in the multivariate analysis. On
multivariate analysis including the age of 63 y, polyp size
of 1.2 cm, and GP/L ratio, the GP/L ratio remained the most
significant, followed by the age. The statistical significance
of size deteriorated on the multivariate analysis.
Table 3 shows the sensitivity, specificity, positive predic-
tive value (PPV), negative predictive value (NPV), and ac-
curacy using the cutoff values of the 3 parameters derived
from 18F-FDG uptake in the GPs. The GP/L ratio again
yielded the highest values. However, the McNemar test
yielded no significant difference in performance between
any pair of these 3 variables.
The retrospectively determined cutoff GP/L ratio of
1.14 yielded false-negative results in 3 (1 adenocarcinoma
and 2 adenomas with high-grade dysplasia) of the 20
patients with malignancy and false-positive results in 4 (3
of the 4 tubular adenomas and 1 of the 12 inflammatory
polyps) of the 30 patients with benign GPs. None of the
cases of adenomyomatosis (n 5 3), cholesterol polyps (n 5
9), or papillary epithelial hyperplasia (n 5 2) were falsely
positive.
DISCUSSION
GPs consist of true neoplasms, such as benign adenomas
and adenocarcinomas, and nonneoplastic polyps, such as
cholesterol polyps, inflammatory polyps, and adenomyom-
atous hyperplasia. Of the benign GPs, the cholesterol polyp
is reported to be the most common type (5,14,19–21). How-
ever, the most common benign GP in our patients included
in this study was the inflammatory polyp associated with
cholecystitis (40%; 12/30). The relatively lower number of
cholesterol polyps (30%; 9/30), compared with inflam-
matory polyps, in our report might have partly resulted
from our selection criteria (i.e., most cholesterol polyps
were smaller than 1 cm, and many of them were likely
excluded).
Most malignant GPs were reported to be larger than
1 cm, with a sensitivity of 88%, yet the PPV of the 1-cm
cutoff size for malignancy ranges widely from 31% to 78%
(4,22). Of the 50 lesions of 1–2 cm included in our study,
malignancy was found in 18 (16 gallbladder cancers and 2
adenomas with focal malignant transformation), translating
to a PPV of 36% for the 1- to 2-cm size criterion for ma-
lignancy. The PPV of the 1-cm-or-greater size criterion
should have been somewhat higher, if GPs greater than
2 cm were included. Regardless, this result certainly ap-
pears within the range of the reported PPVs, indirectly in-
dicating that our patient population is probably not different
from others in the literature.
Patients with malignant GPs were significantly older than
those with benign GPs (65.5 6 10.5 y vs. 55.5 6 10.4 y,
P 5 0.002). The 2 most common cutoff ages used for risk
stratification in the literature are 50 y (7,9) and 60 y (4,5,8).
We found the optimal cutoff in our 1- to 2-cm GPs to be
63 y, which is closer to the cutoff age of 60 y than 50 y.
However, although our results confirm that age is one of the
TABLE 1
Comparison of Mean or Median Values of 4 Continuous Variables Between Benign and Malignant GPs
Variable
Benign (n 5 30) Malignant (n 5 20)
PMean 6 SD Median Range Mean 6 SD Median Range
Age (y) 55.5 6 10.4 34–73 65.5 6 10.5 40–79 0.0018*
Polyp size (cm) 1.35 6 0.33 1.0–2.0 1.51 6 0.32 1.0–2.0 0.1008*
SUVgp (g/mL) 1.63 1.0–6.0 3.28 1.2–6.1 0.0012†
GP/L ratio 0.82 0.46–2.96 1.49 0.46–4.55 0.0001†
*P value by independent Student t test.
†P value by Mann–Whitney test.
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significant risk factors, it was not as significant as variables
derived from 18F-FDG uptake.
Accuracies of 18F-FDG PET for differentiating malig-
nant from benign gallbladder disease reported in 3 prior
studies range from 72% to 84% (16–18). However, these
results are not generalizable. The number of patients was
relatively small—that is, 32 patients in 1 study (18) and 16
patients each in 2 studies (16,17). The small number of
patients is compounded further by the heterogeneous pop-
ulations, either mixing those with diffuse thickening and
those with polypoid lesion (17) or including those with
relatively large tumors (16). Also, the size (17,18) or the
presence or absence of benign polypoid lesions (18) was
not described. The median SUVgp in benign and malignant
GPs in our series was 1.63 and 3.28, respectively. These are
considerably lower than the SUVs of 5.4 (benign) and 7.35
(malignant) reported by Nishiyama et al. (18). The average
SUVof tumor lesions reported by Rodriguez et al. (17) was
4.1, also higher than our values, despite the fact that their
unit was a mean SUV whereas ours was a maximum SUV.
Therefore, the real difference between our values and theirs
is probably even greater. We strongly believe that the rela-
tively lower SUVs in our study resulted from the well-
known partial-volume effect (23–25) because all our GPs
were in the 1- to 2-cm range. Last, because none of the 3
investigations used a fused PET/CT system, potential errors
could have been introduced in SUV measurement, espe-
cially when GPs could not be visually separated from sur-
rounding tissue. Direct coregistration of PET and CT
images should yield more accurate results both visually
and quantitatively than mental coregistration of separately
obtained PET and CT images.
The results from our 50 patients, all with polypoid
lesions of diagnostically challenging size in terms of risk
stratification (i.e., 1–2 cm), indeed show that 18F-FDG up-
take in GPs is a powerful tool for risk stratification. The
TABLE 2
Correlation of Dichotomized Variables with Histopathologic Diagnoses
Variable
Benign
(n 5 30)
Malignant
(n 5 20)
Univariate analysis Multivariate analysis
Odds
ratio
95% confidence
interval P
Odds
ratio
95% confidence
interval P
Sex
Male 15 (63) 9 (37) 1
Female 15 (58) 11 (42) 1.2 0.4–3.8 0.729 —
Age (cutoff, 63 y)
#63 24 (80) 6 (20) 1
.63 6 (30) 14 (70) 9.3 2.5–34.6 0.0008 22.8 2.1–231.3 0.011
Gallstone
No 25 (60) 17 (40) 1
Yes 5 (63) 3 (37) 0.9 0.2–4.2 0.875 —
Polyp size (cm)
#1.2 16 (76) 5 (24) 1
.1.2 14 (48) 15 (52) 3.4 1.0–11.9 0.052 4.9 0.6–39.5 0.140
Visual 18F-FDG uptake
,liver 24 (86) 4 (14) 1
$liver 6 (27) 16 (73) 16.0 3.9–65.8 0.0001 —
SUVgp (g/mL)
#2.1 23 (85) 4 (15) 1
.2.1 7 (30) 16 (70) 13.1 3.3–52.5 0.0003 —
GP/L ratio
#1.14 26 (90) 3 (10) 1
.1.14 4 (19) 17 (81) 36.8 7.3–185.6 0.00001 55.7 5.5–558.8 0.0006
Data in parentheses are percentages.
TABLE 3
Overall Performance of Cutoff Values of 3 Parameters Derived from 18F-FDG Uptake by GPs
Variable Sensitivity Specificity PPV NPV Accuracy AUC
Visual 18F-FDG uptake 80% 80% 73% 86% 80% 0.800
SUVgp (cutoff value, 2.1 g/mL) 80% 77% 70% 85% 78% 0.772
GP/L ratio (cutoff value, 1.14) 85% 87% 81% 90% 86% 0.822
AUC 5 area under curves by receiver-operating-characteristic analyses.
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visual grading, cutoff SUVgp of 2.14, and cutoff GP/L ratio
of 1.14 yielded accuracy of 80%, 78%, and 84%, with
an area under the ROC curve of 0.800, 0.772, and 0.822,
respectively. Although there was no statistically significant
difference in diagnostic performance among these 3
parameters, the SUVgp yielded the lowest values. More-
over, it is well known that variations in SUV may result
from factors unrelated to the patient, such as reconstruction
methods (26,27) and different PET/CT systems from dif-
ferent manufacturers (28), whereas the SUV variations re-
lated to the patient, such as body composition and habitus
(29,30), length of uptake period (31), and blood glucose
level (32), are problems common to all laboratories. There-
fore, we believe that the GP/L ratio or the visual criteria
would be more generalizable and should be used by other
laboratories.
Laparoscopic cholecystectomy is a relatively simple
procedure. If this procedure is to be used in every patient
with a GP, the value of PET would be limited despite its
high NPV and overall efficacy. However, surgeons may feel
that the results from PET, when combined with other
available clinical information, are useful in decision
making not only in terms of laparoscopic procedure versus
open laparotomy but also wide excision versus limited
resection if the latter is to be performed. The utility of PET
in this context is currently under investigation.
This was a retrospective investigational study. Therefore,
inherent bias in patient selection related to the retrospective
nature might have been introduced. Nonetheless, some
of the more obvious limitations existing in the previous
reports were partially overcome by studying a larger, more
homogeneous group of patients with GPs, by excluding
those with gallbladder wall thickening only, and by the use
of additional coregistered CT images. Therefore, we believe
that the results from this study provide new insight as to the
true value of 18F-FDG PET/CT for differentiating malig-
nant from benign GPs.
CONCLUSION
Our data show that 18F-FDG uptake in GPs is a useful
predictor in risk stratification for surgical intervention, per-
haps more effective than many other known risk factors.
The cutoff polyp-to-liver 18F-FDG uptake ratio of 1.14 and
visual grading, compared with liver activity, were both as-
sociated with a reasonably high diagnostic efficacy, even
when used in isolation. All criteria related to 18F-FDG
uptake presented in this series were based on the GPs in
the 1- to 2-cm range. Therefore, these criteria may be ap-
plicable in assessing similar-sized polyps only.
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